{"id":235933,"date":"2026-04-25T22:16:49","date_gmt":"2026-04-26T03:16:49","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/04\/three-year-patient-reported-outcomes-from-bimekizumab-for-plaque-psoriasis-the-be-radiant-randomized-clinical-trial-with-open-label-extension"},"modified":"2026-04-25T22:16:49","modified_gmt":"2026-04-26T03:16:49","slug":"three-year-patient-reported-outcomes-from-bimekizumab-for-plaque-psoriasis-the-be-radiant-randomized-clinical-trial-with-open-label-extension","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/04\/three-year-patient-reported-outcomes-from-bimekizumab-for-plaque-psoriasis-the-be-radiant-randomized-clinical-trial-with-open-label-extension","title":{"rendered":"Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/three-year-patient-reported-outcomes-from-bimekizumab-for-plaque-psoriasis-the-be-radiant-randomized-clinical-trial-with-open-label-extension.png\"><\/a><\/p>\n<p>In a phase 3b randomized clinical trial with open-label extension, bimekizumab demonstrated rapid and sustained improvement in patient-reported outcomes and clinical measures for individuals with moderate to severe PlaquePsoriasis.<\/p>\n<p>By week 4 and through 3 years, a majority of patients reported no itching, skin pain, or scaling, and achieved Dermatology Life Quality Index (DLQI) scores reflecting minimal or no impact on daily life.<\/p>\n<p>Patients switching from secukinumab to bimekizumab at 1 year experienced improvements in perceived symptoms and quality of life comparable to those continuously treated with bimekizumab.<\/p>\n<hr>\n<p>This randomized clinical trial with an open-label extension assesses patient-reported and clinical outcomes among patients with moderate to severe plaque psoriasis treated with bimekizumab.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a phase 3b randomized clinical trial with open-label extension, bimekizumab demonstrated rapid and sustained improvement in patient-reported outcomes and clinical measures for individuals with moderate to severe PlaquePsoriasis. By week 4 and through 3 years, a majority of patients reported no itching, skin pain, or scaling, and achieved Dermatology Life Quality Index (DLQI) scores [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-235933","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/235933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=235933"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/235933\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=235933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=235933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=235933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}